Lupin Ltd (LUPIN) — Announcement | 28 August 2026

28 August 2026 · BSE 🔴 High Importance Neutral

By StockFin Research Team•AI-Assisted Analysis•Source: BSE/NSE Filings

📢 Key Event

Lupin receives Crisil ESG rating of 69 and Core ESG rating of 65 for FY26

💡 Investor Takeaway

The ESG rating reflects strong performance in environmental, social, and governance practices, which may enhance investor perception and sustainability-focused investment appeal.

Lupin Limited announced it received an ESG rating of Crisil ESG 69 and a Core ESG rating of Crisil Core ESG 65 for FY26 from Crisil ESG Ratings, an independent agency that evaluated the company using publicly available information without any prior engagement, placing Lupin in the 'Strong' category.

📄 View Original Announcement (PDF)

📊 Stock Analysis — LUPIN ✨ Ask AI About This

About Lupin Ltd (LUPIN)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹94,274.49 CrP/E: 16.6ROE: 24.6%ROCE: 27.9%Div Yield: 0.87%

View full LUPIN stock details →

📡 Get AI alerts when LUPIN files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track LUPIN — Free

💡 Ask AI about this filing

"How does Lupin's ESG rating compare to peers like Sun Pharma or Dr. Reddy's?""What specific initiatives contributed to achieving a 'Strong' ESG category?""Will this rating affect Lupin's access to ESG-focused funding or indices?"

Ask AI Free →

📊 More LUPIN filings

🔴 Announcement — 28 September 2026Lupin announced that its U.S. subsidiary received tentative FDA approval for a novel apixaban oral s...
Announcement — 28 September 2026Lupin Ltd announced that its insider trading window will close on October 1, 2026, and remain shut u...
🔴 Corporate Action — 21 September 2026Lupin announced on September 21, 2026, the allotment of 24,111 fully paid-up equity shares of ₹2 eac...
🔴 Announcement — 8 September 2026Lupin Ltd announced its participation in two upcoming investor events: the Kotak Healthcare Conferen...
🔴 Announcement — 4 September 2026Lupin announced that the U.S. FDA approved its ANDA for Modafinil Tablets USP 100 mg and 200 mg, mar...

See all LUPIN filings →

🔥 Also filed on 28 August 2026

BLILBalmer Lawrie Investment LtdAnnual Report 520075Samkrg Pistons & Rings LtdAnnual Report 507998Simmonds Marshall LtdAnnual Report BLUEDARTBlue Dart Express LtdAnnual Report TTLT T LtdInsider Trading LTFL&T Finance LtdCorporate Action

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when LUPIN files new disclosures

Track LUPIN filings, board meetings, and corporate actions. Free email alerts at 5 PM.